Biogen beats on earnings but guidance falls short

12 February 2025

Biogen (Nasdaq: BIIB) reported fourth-quarter 2024 earnings that surpassed analysts' expectations, driven by strong sales of new product launches.

However, the company’s 2025 guidance fell below consensus estimates, as declining revenue from its multiple sclerosis portfolio weighed on overall growth. Biogen’s stock has fallen 43% over the past 12 months, underperforming the broader biotech sector and the S&P 500.

In the fourth quarter, the firm posted revenue of $2.4 billion, up 3% from the prior year and a little above what most analysts expected. Net income rose to $267 million, or $1.83 per share, from $250 million, or $1.71 per share, a year earlier. Adjusted earnings per share were $3.44, exceeding the FactSet consensus of $3.35.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK